Tag: Non-steroidal aromatase inhibitor (third generation)

  • Anastrozole

    Third-generation nonsteroidal aromatase inhibitor (triazole derivative)

    A potent, selective, reversible nonsteroidal aromatase inhibitor developed at Zeneca Pharmaceuticals for the adjuvant treatment of estrogen receptor-positive breast cancer, distinguished from steroidal inactivators by triazole-mediated competitive binding, oral bioavailability, and a long terminal half-life permitting once-daily dosing.

    Abstract

    Anastrozole (ZD1033, Arimidex) is a third-generation nonsteroidal aromatase inhibitor of the triazole class that selectively and reversibly inhibits the cytochrome P450 19A1 (CYP19A1, aromatase) enzyme complex responsible for the terminal step in estrogen biosynthesis: the conversion of androstenedione to estrone and testosterone to estradiol. The compound was developed at Zeneca Pharmaceuticals (now AstraZeneca) through systematic optimization of triazole-bearing aromatase inhibitor scaffolds and received United States Food and Drug Administration approval in 1995 for the treatment of advanced breast cancer in postmenopausal women following tamoxifen therapy, with subsequent label expansions to first-line advanced disease (2000) and adjuvant treatment of early-stage hormone receptor-positive breast cancer (2002).

    The pivotal Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, enrolling 9,366 postmenopausal women with early-stage invasive breast cancer, established anastrozole as superior to tamoxifen on disease-free survival, time to recurrence, time to distant recurrence, and incidence of contralateral breast cancer at 100-month and 10-year analyses, with a carryover benefit extending beyond the 5-year treatment period. Anastrozole is now among the most widely prescribed endocrine therapies in oncology, with established roles in adjuvant, neoadjuvant, extended adjuvant, and chemoprevention settings for estrogen receptor-positive breast cancer.

    Pharmacokinetics are characterized by rapid oral absorption (time to peak concentration approximately 2 hours), high oral bioavailability (approximately 85 percent), extensive hepatic metabolism through N-dealkylation, hydroxylation, and glucuronidation (with a principal inactive triazole metabolite), and a long terminal elimination half-life of 40 to 50 hours that supports once-daily dosing and achieves steady-state plasma concentrations within approximately 7 days. Anastrozole is not a potent inhibitor or inducer of cytochrome P450 enzymes at therapeutic concentrations, and clinically significant drug-drug interactions are uncommon. The compound is well tolerated; the principal adverse events are hot flashes, arthralgia, fatigue, and musculoskeletal stiffness, with the most clinically significant long-term safety signal being accelerated bone mineral density loss and increased fracture risk attributable to profound estrogen suppression, managed in clinical practice through concurrent bisphosphonate therapy and bone density monitoring.

    Beyond the oncology indication, anastrozole has been investigated as an off-label research tool for modulating the hypothalamic-pituitary-gonadal axis in males, where aromatase inhibition reduces the conversion of testosterone to estradiol, relieves estrogen-mediated negative feedback on gonadotropin secretion, and increases endogenous testosterone production. This application remains investigational and is not approved by regulatory authorities. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Letrozole

    Non-steroidal aromatase inhibitor (third generation)

    A potent non-steroidal aromatase inhibitor; superior to anastrozole at suppressing plasma estradiol and used in postmenopausal breast cancer and ovulation induction.

    Abstract

    Letrozole (4,4′-(1H-1,2,4-triazol-1-ylmethylene)bis(benzonitrile); CAS 112809-51-5; molecular formula C17H11N5; molecular weight 285.31) is a non-steroidal third-generation aromatase inhibitor developed at Novartis and approved by the FDA in 1997 under the trade name Femara. The greater potency translates to slightly superior progression-free survival in head-to-head trials versus anastrozole in metastatic breast cancer, with similar tolerability. Plasma half-life is approximately 42 hours; metabolism is hepatic via CYP2A6 and CYP3A4. Approved indications include adjuvant and metastatic ER-positive postmenopausal breast cancer; off-label use in PCOS-related anovulatory infertility (often more effective than clomiphene per the PPCOS II trial) and as estrogen control in androgen-using populations. Used as the most potent reference aromatase inhibitor.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.